OncoMatch/Clinical Trials/NCT06517888
Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
Is NCT06517888 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies AAVAnc80-antiVEGF via Akouos Delivery Device for vestibular schwannoma.
Treatment: AAVAnc80-antiVEGF via Akouos Delivery Device — This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Prior therapy
Cannot have received: surgery
Prior surgery ... for vestibular schwannoma.
Cannot have received: radiation therapy
Prior ... radiation therapy for vestibular schwannoma.
Cannot have received: gene therapy
any prior participation in a gene therapy clinical trial.
Cannot have received: investigational drug
Prior participation in a clinical trial with an investigational drug within six months prior to administration (Day 0)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Johns Hopkins Hospital · Baltimore, Maryland
- Mayo Clinic · Rochester, Minnesota
- Vanderbilt Bill Wilkerson Center · Nashville, Tennessee
- University of Texas Southwestern · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06517888 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior surgery, radiation therapy, gene therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify